...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current drug targets-The International journal for timely in-depth reviews on drug targets >Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy
【24h】

Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy

机译：使用单克隆抗体靶向受体酪氨酸激酶：针对基于靶标的癌症治疗的最具体工具

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Receptor tyrosine kinases (RTKs) family is comprised of different cell surface glycoproteins. These enzymes participate in and regulate vital processes such as cell proliferation, polarity, differentiation, cell to cell interactions, signaling, and cell survival. Dysregulation of RTKs contributes to the development of different types of tumors. RTKs deregulation in different types of cancer has been reported for more than 30 RTKs. Due to their critical roles, the specific targeting of RTKs in malignancies is a promising approach. Targeted cellular and molecular therapies (personalized medicine) have been known as new types of therapeutics, which prevent tumor cell proliferation and invasion by interfering with molecules essential for tumor growth and survival. Specific targeting of RTKs using monoclonal antibodies (mAbs) in malignancies as well as in autoimmune disorders is of great interest. The growing number of mAbs approved by the authorities implies on the increasing attentions and applications of these therapeutic tools. Due to the high specificity, mAbs are the most promising substances that target RTKs expressed on the tumor cell surface. In this communication, we review the recent progresses in the development of mAbs targeting oncogenic RTKs for cancer treatment.
机译：受体酪氨酸激酶（RTKs）家族由不同的细胞表面糖蛋白组成。这些酶参与并调节重要过程，例如细胞增殖，极性，分化，细胞间相互作用，信号传导和细胞存活。 RTKs的失调促进了不同类型肿瘤的发展。已经报道了超过30种RTK在不同类型癌症中的RTK失控。由于它们的关键作用，RTK在恶性肿瘤中的特异性靶向是一种有前途的方法。靶向细胞和分子疗法（个性化药物）已被称为新型疗法，可通过干扰肿瘤生长和存活所必需的分子来防止肿瘤细胞增殖和侵袭。使用单克隆抗体（mAb）在恶性肿瘤以及自身免疫性疾病中对RTK的特异性靶向引起了极大的兴趣。当局批准的mAb数量不断增加，意味着这些治疗工具的关注和应用日益增加。由于高特异性，mAb是靶向肿瘤细胞表面表达的RTK的最有希望的物质。在本通讯中，我们回顾了针对致癌RTKs的单克隆抗体在癌症治疗中的最新进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号